Investigators aimed to determine whether vaporized cannabis would reduce symptoms of chronic pain in adult patients with sickle cell disease.
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
The MPN Genomic Calculator uses clinical, laboratory, and genomic characteristics of patients with MPN to estimate their clinical outcomes.
Among patients with
FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
Some tyrosine kinase inhibitors may cause a hyperinflammatory response.
Risk-adapted therapy effectively prevents fungal infections and reduces neurotoxicity in children with leukemia.
Data from Spain add to the knowledge of Richter syndrome.
Combined ofatumumab and hyper-CVAD is a safe and active treatment for adult patients with (Ph)-negative, CD20-positive B-cell ALL.
The management of CLL, including delays in work-up and treatment, and modifications to clinical trials, have been implemented across Italy in response to the COVID-19 pandemic.
Helsinn and MEI Pharma have discontinued a phase 3 study evaluating pracinostat, in combination with azacitidine, for frontline treatment of older patients with acute myeloid leukemia.
At primary analysis, 40% of patients assigned to the venetoclax arm vs 31% of those assigned to placebo were alive.
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
The current state of AML treatment and remaining needs are discussed in an interview with Courtney D. DiNardo, MD, MSCE and Ghayas C. Issa, MD.
Greater intake of foods rich in antioxidants tied to lower rates of infection, mucositis during treatment.
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
Patients with B-cell ALL who are treated with CAR T-cell therapy and allo-HSCT may have better outcomes than those treated only with CAR T-cell therapy.
For patients with AML, high immunoglobulin expression is linked to monocytic differentiation, dysplasia, and poorer prognosis.
In this patient case, significant neurological adverse effects associated with nelarabine were noted at 30 days following initiation of therapy.
A study compared the effects of intrathecal triple therapy to intrathecal methotrexate on disease-free survival among patients with B-ALL.
The FDA has expanded the approval of Mylotarg (gemtuzumab ozogamicin; Pfizer) to include treatment of patients aged 1 month and older with newly-diagnosed CD33-positive acute myeloid leukemia.
Among adult patients with newly diagnosed AML, the presence of an
FLT3-ITD mutation with an insertion site in the beta1-sheet was associated shorter survival.
In this study, obinutuzumab, ibrutinib, and venoclax were administered as first-line therapy in patients with CLL characterized by del(17p) and/or TP53 mutation.
The addition of venetoclax to azacitidine was associated with a 34% reduction in risk of death.
In an updated analysis, venetoclax plus low-dose cytarabine improved OS compared with placebo among patients with untreated AML who were ineligible for intense chemotherapy.
For patients with r/r CLL, acalabrutinib significantly improved progression-free survival compared with idelalisib-rituximab or bendamustine-rituximab.
Investigators compare efficacy and safety of obinutuzumab/chlorambucil, rituximab/ chlorambucil, and rituximab/bendamustine as frontline CLL treatments.
In this study, the incidence of laboratory tumor lysis syndrome was 13% in a cohort of patients with relapsed CLL treated with venetoclax in a “real world” setting.
Promising follow-up data on safety and efficacy of fixed-duration venetoclax-obinutuzumab for patients with untreated CLL.
Physicians noted that patients receiving best supportive care were more likely to be interested in low-intensity treatments if the risk for side effects was lower.
Despite survival improvements in refractory anemia compared with other subtypes of MDS, patients may still have an increased risk for secondary AML.
Researchers reported long-term follow up from the first clinical trial of anti-CD19 CAR T cells that revealed responses against lymphoma.
Researchers outlined a validated p-DRI for AML and ALL that successfully stratifies children undergoing allogeneic hematopoietic cell transplantation for prognostication.
Generating CAR T cells against human cognate receptor CD117 may be a successful treatment for patients with AML.
Encouraging response rates in children with first relapse AML treated with CPX-351 followed by FLAG provide rationale for de novo AML study.
The incidence of DLBCL among Hispanic individuals and CLL among non-Hispanic black individuals was associated with urban status.
Novel treatment options are needed to improve outcomes for patients with
TP53-mutated myeloid neoplasms.
Two extraction and amplification methods for gene expression analyses on residual leukemic cells may improve future studies when working with fewer cells.
Based on results of pharmacodynamics analyses, the phase 2 study protocol was amended to only include a 100 mg, twice-daily dosing of acalabrutinib.
Pediatric patients with AML may benefit from dexrazoxane as a cardioprotectant during first-line anthracycline therapy.
The Connect CLL Registry revealed that real-world treatment outcomes for patients with CLL who were treated in the community setting differed from trial results.
Smoking associated with inferior survival among patients receiving intensive chemotherapy for AML.
A higher dose of anti-CD19 CAR-T resulted in similar toxicities, but higher ORR and longer PFS, compared with a lower dose in patients with relapsed/refractory CLL.
Acalabrutinib, administered as monotherapy or in combination with obinutuzumab, may be an effective first-line therapy to improve outcomes in CLL.
A first-in-human, universal CAR-T therapy was tolerable and showed activity against relapsed/refractory T-ALL in a phase 1 study.
A novel, bispecific CD19/CD22 CAR-T therapy was tolerable and led to responses in a phase 1, dose-escalating study.
Increased bone marrow
MUC4 expression is associated with reduced remission persistence and exacerbated survival in patients with acute myeloid leukemia.
The FDA has approved the supplemental New Drug Application for Imbruvica® (ibrutinib;Janssen) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.